(Q53234224)

12 May 2018

title

Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. (English)

1 reference

12 May 2018

main subject

hepatocellular carcinoma

1 reference

4

1 reference

12 May 2018

author name string

Sabine Irtan

1

1 reference

12 May 2018

Xavier Chopin-Laly

2

1 reference

12 May 2018

Maxime Ronot

3

1 reference

12 May 2018

Valérie Paradis

5

1 reference

12 May 2018

Jacques Belghiti

6

1 reference

12 May 2018

publication date

11 January 2011

1 reference

12 May 2018

published in

Liver International

1 reference

12 May 2018

volume

31

1 reference

12 May 2018

issue

5

1 reference

12 May 2018

page(s)

740-743

1 reference

12 May 2018

Sorafenib in advanced hepatocellular carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2010.02441.X

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2010.02441.X

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2010.02441.X

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2010.02441.X

Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2010.02441.X

10.1111/J.1478-3231.2010.02441.X

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018